Sun Pharma Monday said it will acquire Japan-based Pola Pharma for around USD 1 million to strengthen its presence in dermatology segment across the globe.
The company has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharmaceutical Industries said in a statement.
Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables.
It also has R&D capabilities to develop new technologies and formulations.
"This acquisition is in line with our strategy to strengthen our global dermatology presence. Pola Pharma is a leading dermatology company and it will help us launch our speciality and generic dermatology products in the Japanese market in future," Sun Pharma Executive Vice-President Kirti Ganorkar said.
Sun Pharma Japan Country Head ..

Sun Pharma

<div>
	
	Sun Pharma on Monday said it would acquire Japan-based Pola Pharma for $1 million to strengthen its presence in dermatology segment across the globe.&nbsp;</div>
<br>
<div>
	The firm has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharma said.&nbsp;</div>
<br>
<div>
	Pola Pharma&#39;s portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama, with capabilities to manufacture topical products and injectables.</div>

Sun Pharma Monday said it will acquire Japan-based Pola Pharma for around USD 1 million to strengthen its presence in dermatology segment across the globe.
The company has entered into a definitive agreement to acquire Pola Pharma, which is engaged in research and development, manufacture, sale and distribution of branded and generic products in Japan, Sun Pharmaceutical Industries said in a statement.
Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama with capabilities to manufacture topical products and injectables.
It also has R&D capabilities to develop new technologies and formulations.
"This acquisition is in line with our strategy to strengthen our global dermatology presence. Pola Pharma is a leading dermatology company and it will help us launch our speciality and generic dermatology products in the Japanese market in future," Sun Pharma Executive Vice-President Kirti Ganorkar said.
Sun Pharma Japan Country Head ...

Sun Pharma to acquire Japan's Pola Pharma for $1 million for derma products

Pola Pharma's portfolio mainly comprises dermatology products. It has two manufacturing facilities in Saitama, with capabilities to manufacture topical products and injectables

More From This Section

Asset sale to Jio at risk from govt's Rs 29-bn demand, RCom tells SC

Debt-laden Jet Airways fires 16, pay problems to persist till March

Rupert Murdoch's group bets Fox News fans will follow network online

Apple gets US top court's scepticism in lawsuit over price of apps

Explore News